Business
Anixa Biosciences Names Cancer Vaccine Pioneer Dr. Ian H. Frazer to Scientific Advisory Board
SAN JOSE, Calif., Oct. 10, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system
About this update from Anixa Biosciences, Inc.
[{"type":"text","content":"SAN JOSE, Calif., Oct. 10, 2019 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body's immune system to fight cancer, today announced the appointment of Ian H. Frazer, MD, AC, FRS, FAA, to its Scientific Advisory Board. \nDr. Frazer is a leading immunologist recognized as one of the first scientists to study the link between immunity to human papillomavirus (HPV) infection and cervical cancer. His research began more than 25 years ago when he and his colleague, the late Jian Zhou, MD, co-invented a technology for virus-like particles that trigger an immune response against HPV. This breakthrough became the basis of two approved cancer vaccines, Gardasil® and Cervarix®. These two vaccines are highly effective in protecting against HPV associated infection which is known to be the cause of cervical and other cancers.\n\"We are honored to have such a distinguished scientist join our Scientific Advisory Board,\" stated Amit Kumar, PhD, President and Chief Executive Officer of Anixa Biosciences. \"Dr. Frazer's discoveries have enabled us to believe, with effective global vaccination, that the world can rid itself of cervical cancer. With his unique knowledge of vaccine technology, Dr. Frazer joins us at an opportune time, as we have expanded our therapeutic portfolio with a prophylactic cancer vaccine that has the potential to eliminate certain types of breast cancer.\"\n\"I look forward to working with the Anixa team,\" commented Dr. Frazer. \"The vaccine technology invented at the Cleveland Clinic is an exciting approach to prophylactic (preventive) vaccination. I am excited to lend my experience and expertise to enable testing this novel immunological approach in humans.\"\nAbout Ian H. Frazer, MD, AC, FRS, FAADr. Ian Frazer is a professor at the University of Queensland where he leads a research team working at the Translational Research Institute (TRI) in Brisbane, Australia on the immunobiology of epithelial cancers. Additionally, he currently serves as the President of the Australian Academy of Health and Medical Sciences, and as a member of the Australian National Health and Medical Research Council. He also chairs the Australian Medical Research Advisory Board of the Medical Research Future Fund. In addition to his positions in science and academia, Dr. Frazer serves ...